

ERNEST D. BUFF & ASSOCIATES, LLC

Intellectual Property Solutions

245 South Street
Morristown, NJ 07960
(973) 644-0008
FAX (973) 644-4554

RECEIVED
CENTRAL FAX CENTER

SEP 22 2003

OFFICIAL

FAX COVER SHEET

Date: September 19, 2003
From: Roger H. Criss
Client/Matter #: 0147-1
Re: Serial No. 09/828,330, Filed April 6, 2001

Pages sent (including cover): 18

RECIPIENT	FIRM	CC:	FAX NUMBER
Examiner C. Nichols	USPTO - Art Unit 1647		703-872-9307


Message:

Dear Dr. Nichols:

Enclosed for your information is a copy of the Amendment after Final Rejection that has been mailed today to the USPTO. The reason that the official copy is being mailed is because a check was required for the extension of time. However, I thought that you would like a copy at this time.

Should there be any questions, please let me know.

Respectfully submitted,



Roger H. Criss
Reg. No. 25,570

Enclosure

Confidentiality Note:

The documents accompanying this telecopy transmission contain information from the law firm of Ernest D. Buff & Associates, LLC, which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named in the transmittal sheets. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopy is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone so that we can arrange for the return of the original documents to us at no cost to you.

Serial No. 09/828,330

Amendment after Final Rejection dated September 19, 2003

Reply to Final Rejection dated June 10, 2003

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-15 (canceled)

Claim ~~10~~¹ (currently amended): A method for the systematic, multi-tiered treatment of coronary artery disease by delivery of a formulation comprising one or more therapeutic growth factor proteins, the method comprising the steps of:

- a.) selecting a patient displaying symptoms of acute coronary artery disease;
- b.) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof, by inhalation therapy;
- c.) monitoring one or more clinical indicators of acute coronary artery disease;
- d.) determining, based on monitoring the one or more clinical indicators of coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is necessary;
- e.) depending on the results of the step d.), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof; and
- f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of acute coronary artery disease in the patient, or until there is a contraindication to continued treatment.

Serial No. 09/828,330

Amendment after Final Rejection dated September 19, 2003

Reply to Final Rejection dated June 10, 2003

Claim ²~~17~~ (currently amended): The method of claim ¹~~16~~ [(New)], wherein the second growth factor protein is administered by a method of delivery more invasive than the method of delivery utilized for administration of the first growth factor protein formulation.

Claim ³~~18~~ (currently amended): The method of claim ¹~~16~~ [(New)], wherein the second growth factor protein is administered by the same method of delivery utilized for administration of the previous dose.

Claim ⁴~~19~~ (currently amended): The method of claim ¹~~16~~ [(New)], wherein the one or more clinical indicators of acute coronary artery disease are selected from the group consisting of levels of CPK-MB, electrocardiogram tracings, and chest pain.

Claim 20 (canceled)

Claim ⁵~~21~~ (currently amended): The method of claim ¹~~16~~ [(New)], wherein the symptoms of acute coronary artery disease are brought on by a condition selected from the group consisting of myocardial infarct, unstable angina, and acute anginal attack.

Claim ⁶~~22~~ (currently amended): The method of claim ¹~~16~~ [(New)], wherein the method of delivery of the second growth factor protein formulation is selected from the group consisting of oral inhalation, intravenous administration, intracoronary infusion, intrapericardial injection, myocardial introduction via catheter during cardiac catheterization, and direct myocardial injection.

Claim ⁷~~23~~ (currently amended): The method of claim ¹~~16~~ [(New)], wherein the growth factor formulation administered in step e.) and subsequent steps is the same as the growth factor formulation administered initially.

Claim ⁸~~24~~ (currently amended): The method of claim ¹~~16~~ [(New)], wherein the growth factor formulation administered in step e.) and subsequent steps is different from the growth factor formulation administered initially.

Serial No. 09/828,330

Amendment after Final Rejection dated September 19, 2003

Reply to Final Rejection dated June 10, 2003

Claims 25-34 (canceled)

Claim ¹⁵~~25~~ (currently amended): A method for the systematic, multi-tiered treatment of chronic coronary artery disease by delivery of a formulation comprising one or more therapeutic growth factor proteins, the method comprising the steps of:

- a.) selecting a patient displaying symptoms of chronic coronary artery disease;
- b.) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein being selected from the group consisting of EGF-1, FGF-2, VEGF, and mixtures thereof, by inhalation therapy;
- c.) monitoring one or more clinical indicators of chronic coronary artery disease;
- d.) determining, based on monitoring the one or more clinical indicators of chronic coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is necessary;
- e.) depending on the results of the step d.), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of EGF-1, FGF-2, VEGF, and mixtures thereof; and
- f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of chronic coronary artery disease in the patient, or until there is a contraindication to continued treatment.

Claim ¹⁶~~36~~ (currently amended): The method of claim ¹⁵~~36~~ [(New)], wherein the amelioration of symptoms is achieved as a result of a clinically significant amount of angiogenesis.

Serial No. 09/828,330

Amendment after Final Rejection dated September 19, 2003

Reply to Final Rejection dated June 10, 2003

¹⁷
Claim ~~27~~ (currently amended): The method of claim ~~25~~¹⁵ [[(New)]]], wherein the second growth factor protein formulation is administered by the same method of delivery utilized for the administration of the previous dose.

¹⁸
Claim ~~38~~ (currently amended): The method of claim ~~35~~¹⁵ [[(New)]]], wherein the second growth factor protein formulation is administered by a method of delivery more invasive than the method of delivery utilized for the administration of the first growth protein formulation.

¹⁹
Claim ~~39~~ (currently amended): The method of claim ~~35~~¹⁵ [[(New)]]], wherein the one or more clinical indicators of chronic coronary artery disease are selected from the group consisting of frequency and intensity of anginal symptoms, myocardial perfusion, electrocardiogram tracings, scores on quantitative angina scales, and angiography.

Claim 40 (canceled)

²⁰
Claim ~~41~~ (currently amended): The method of claim ~~35~~¹⁵ [[(New)]]], wherein the method of delivery of the second growth factor protein formulation is selected from the group consisting of oral inhalation, intravenous administration, intracoronary infusion, intrapericardial injection, myocardial introduction *via* catheter during cardiac catheterization, introduction during transmyocardial revascularization and direct myocardial injection.

²¹
Claim ~~42~~ (currently amended): The method of claim ~~35~~¹⁵ [[(New)]]], wherein the growth factor formulation administered in step e.) and subsequent steps is the same as the growth factor formulation administered initially.

²²
Claim ~~43~~ (currently amended): The method of claim ~~35~~¹⁵ [[(New)]]], wherein the growth factor formulation administered in step e.) and subsequent steps is different from the growth factor formulation administered initially.

Claims 44-53 (canceled)

Serial No. 09/828,330

Amendment after Final Rejection dated September 19, 2003

Reply to Final Rejection dated June 10, 2003

⁹
Claim ~~54~~ (new): The method of claim ~~10~~¹, wherein each of said first and second therapeutic growth factor protein formulations comprise FGF-1 and/or FGF-2.

¹⁰
Claim ~~55~~ (new): The method of claim ~~10~~¹, wherein each of said first and second therapeutic growth factor protein formulations comprise VEGF.

²³
Claim ~~56~~ (new): The method of claim ~~25~~¹⁵, wherein each of said first and second therapeutic growth factor protein formulations comprise FGF-1 and/or FGF-2.

²⁴
Claim ~~57~~ (new): The method of claim ~~25~~¹⁵, wherein each of said first and second therapeutic growth factor protein formulations comprise VEGF.

¹¹
Claim ~~58~~ (new): The method of claim ~~10~~¹, wherein at least one of said first and second therapeutic growth factor protein formulations is a dry powder formulation.

¹²
Claim ~~59~~ (new): The method of claim ~~10~~¹, wherein at least one of said first and second therapeutic growth factor protein formulations is a liquid aerosol formulation.

¹³
Claim ~~60~~ (new): The method of claim ~~10~~¹, wherein the acute symptoms of heart disease are brought on by reperfusion injury.

¹⁴
Claim ~~61~~ (new): The method of claim ~~60~~¹³, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.